2025-05-02 09:29:22
Latest Post
Godrej Agrovet Limited consolidated Q4FY25 net profit drops QoQ to Rs. 70.78 crores
L G Balakrishnan & Bros Ltd posts Rs. 84.03 crores consolidated profit in Q4FY25
Swastika Investmart Ltd Q4 FY2025 consolidated profit slumps to Rs. 27.17 lakhs
Vertex Securities Ltd consolidated Q4 FY25 loss at Rs. 53.99 lakhs
The Federal Bank Limited consolidated Q4FY25 PAT jumps to Rs. 1108.31 crores
Stock Report
Marksans Pharma Ltd posts consolidated PAT of Rs. 62.6 crores in Q1FY22
Posted On : 2021-08-11 13:13:48( TIMEZONE : IST )
Marksans Pharma Ltd. has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY 2021-22) - QoQ Comparison
The company has reported total income of Rs.354.84 crores during the period ended June 30, 2021 as compared to Rs.336.21 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.62.6 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.79.49 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.1.51 for the period ended June 30, 2021 as compared to Rs.1.93 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY20-21 | % Change |
| Total Income | ₹ 354.84 crs | ₹ 336.21 crs |  5.54% |
| Net Profit | ₹ 62.6 crs | ₹ 79.49 crs |  -21.25% |
| EPS | ₹ 1.51 | ₹ 1.93 | -21.76% |
Financial Results (Q1 FY 2021-22) - YoY Comparison
The company has reported total income of Rs.354.84 crores during the period ended June 30, 2021 as compared to Rs.331.33 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.62.6 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.49.36 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.1.51 for the period ended June 30, 2021 as compared to Rs.1.20 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 354.84 crs | ₹ 331.33 crs | 7.1% |
| Net Profit | ₹ 62.6 crs | ₹ 49.36 crs | 26.82% |
| EPS | ₹ 1.51 | ₹ 1.20 | 25.83% |
Commenting on the performance Mark Saldanha, Managing Director of the Company said "We recorded a sales growth of 5.4% led by increased penetration in regulated markets despite pandemic induced logistics issues. We drove gains from operating efficiencies and a debt free balance sheet resulting in our bottom line increasing by 26.8% in Q1FY22 on a year on year basis.
We are delighted to have OrbiMed as a financial partner in our mission to become a global pharmaceutical company. We will continue to invest in our businesses, with Orbimed's global network and resources enabling us to accelerate our growth momentum in the long term."
Shares of Marksans Pharma Ltd. was last trading in BSE at Rs. 76.5 as compared to the previous close of Rs. 80.6. The total number of shares traded during the day was 711784 in over 6269 trades.
The stock hit an intraday high of Rs. 81.55 and intraday low of 74.55. The net turnover during the day was Rs. 55549258.
